This medication is the first once-daily injectable derivative of the human incretin glucagon-like peptide-1 recently approved by the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) for the treatment of obesity (adults with a BMI ≥ 30 kg/m2), as well for adults with a BMI of 27 kg/m2 or greater who also have one or more complications related to their weight, such as type 2 diabetes, high blood pressure, high cholesterol or obstructive sleep apnea (6, 7). This evidence concerns the gene GCG and obstructive sleep apnea syndrome.